- In December 2024, Santen Pharmaceutical Co., Ltd. announced that it has received approval for the manufacturing and marketing of RYJUSEA, Mini ophthalmic solution 0.025% (generic name: atropine sulfate hydrate) in Japan, aimed at slowing the progression of myopia. This product is the first ophthalmic solution approved in Japan for suppressing myopia progression
- In April 2024, Viatris Inc. has announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75%, a treatment for pharmacologically-induced mydriasis caused by adrenergic agonists (such as phenylephrine) or parasympatholytic agents (such as tropicamide). RYZUMVI is now the only FDA-approved eye drop in the United States specifically designed to reverse pupil dilation
- In March 2024, Roche Pharma India announced the launch of Vabysmo (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo is the only dual-pathway inhibitor that specifically targets and blocks two key disease pathways associated with various vision-threatening retinal conditions
- In June 2023, Bausch + Lomb Corporation announced that it has reached a definitive agreement with Novartis to acquire XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroidal eye drop specifically approved for treating the signs and symptoms of dry eye disease (DED), with a focus on addressing the inflammation associated with the condition
- In June 2022, Novartis announced its acquisition of Kedalion Therapeutics and its innovative AcuStream™ technology, a device designed to enable precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. This acquisition strengthens Novartis' ophthalmic portfolio and supports its ongoing efforts to explore transformative ophthalmic solutions aimed at addressing unmet patient needs in front-of-eye conditions
